Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Track And Trace Negotiations Continue As Senate Works To Cull Amendments

This article was originally published in The Pink Sheet Daily

Executive Summary

Language in manager’s amendment is considered a placeholder, and a resolution could come when the Senate’s FDA user fee bill reaches the conference committee. But first, the bill needs to pass.

You may also be interested in...



FDA’s Hand-Held Rx Counterfeit Detector Could Roll Out To Developing Nations

Agency meets with USAID stakeholders and wants to maximize the public health impact of its hand-held counterfeit drug detection device, which allows for quick preliminary screening of drug shipments to determine if counterfeit or adulterated product is present.

Opioid Prescriber Education Mandate Could Be Added To User Fee Bill

Sen. Rockefeller introduces amendment that would require 16 hours of training every three years to maintain DEA registration.

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.

Related Content

Topics

UsernamePublicRestriction

Register

PS074157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel